RGLS Rentabilitas operasi Regulus Therapeutics, Inc.

RGLS (Regulus Therapeutics, Inc.) - tandha merek perusahaan

Successes in developing RNA therapies for renal pathologies determine the operating profit margins on the GURU.Markets chart, where 0.00 records a new level. The effective leadership of Jay Hagan has secured capital inflows for scientific research. Meanwhile, operational processes are strictly limited by FDA medical regulations regarding the disposal of biomaterials for Regulus Therapeutics (RGLS).

RGLS: Rentabilitas dodolan operasi Regulus Therapeutics, Inc. 04.07.2022 - 05.07.2025

Rincian metrik keuangan lan pasar Regulus Therapeutics (RGLS)

Analisis wiwitan perusahaan:Regulus, RGLS
Produk merek Regulus

The operating margin reflects the efficiency of the core operations of Regulus Therapeutics (RGLS), representing the share of operating profit in total revenue before accounting for debt and tax obligations. Analyzing this operating margin allows for an assessment of how the fabless model and the outsourcing of production to CMOs optimize costs, which determines the fundamental stability of the business during the development of RNA drugs.

Analisis perusahaan pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Sangamo Therapeutics Inc. - Margin operasi|NAUT - Margin operasi|MGX: Margin operasi|Margin dodolan operasi Precision BioSciences, Inc.|GBIO (Generation Bio) - Margin operasi|Boundless Bio Inc. (BOLD) - Rentabilitas kegiatan operasi|Margin dodolan operasi XCUR (exicuretx.com)|Imunon Inc - Rentabilitas dodolan miturut bathi operasi|Margin operasi PHIO (Phio Pharmaceuticals Corp)|Tingkat bathi operasi MBIO|RNAZ - Rentabilitas operasi|Tingkat bathi operasi BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Rentabilitas operasi|Bluebird Bio - Tingkat bathi operasi|IPA (ImmunoPrecise Antibodies Ltd) - Margin operasi|Rentabilitas dodolan operasi Omega Therapeutics, Inc. OMGA|Margin operasi OMIC|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi